Pharmaceutical manufacturers of Hyaluronic acid

FAREVA stands as a prominent global pharmaceutical CDMO with leading expertise in the development and production of a wide variety of Drug Products and Active Pharmaceutical Ingredients (APIs). The company has a workforce of 13,000 individuals spread across 41 manufacturing facilities situated in 13 countries across EMEA and the Americas. Among these facilities, 18 are exclusively dedicated to pharmaceutical operations. FAREVA’s API division carries out its activities in 3 European locations situated in France and Germany.

Our objective is to pave the path to a more wholesome future. However, we are also concerned about the manner in which we collectively achieve this goal. Being a company whose products impact the well-being of individuals worldwide, we uphold ourselves to a stringent standard and anticipate others to treat us likewise. We are advocates of transparent, truthful, and principled operation with the utmost level of ethics and honesty. This encompasses ensuring the company's compliance with all relevant laws and regulations on a global scale.

Our company is engaged in the manufacturing of active pharmaceutical ingredients in Russia and is in the process of finalizing the construction of our facility in Austria dedicated to the production of pharmaceutical drugs. The active pharmaceutical ingredients are derived using the purest fresh water sourced from a reservoir and powered by sustainable electricity from the Novosibirsk hydroelectric power station

Bloomage Biotechnology Corporation Limited (formerly Bloomage Freda Biopharm) was founded by the Bloomage International Investment Group. It has gained global recognition as a manufacturer of bioactive materials. During the 1990s, it became the pioneering company in China to devise the fermentation process for producing sodium hyaluronate. It has also developed approximately 200 variations of hyaluronic acid utilized in the pharmaceutical, medical devices, cosmetics, and functional foods sectors. Functioning as a raw material business division, Bloomage Biotech delivers inventive solutions and technical assistance to its collaborators. Meanwhile, in 2000, Bloomage Biotech (previously Bloomage Freda Biopharm Co., Ltd.) embarked on its journey as a producer of hyaluronic acid through microbial fermentation. Over two decades later, Bloomage Biotech has positioned itself as a leading global biotechnology and biomaterial enterprise specializing in the industrialization of hyaluronic acid. Bloomage Biotech is committed to enriching people’s lifestyles by establishing healthier experiences